Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. - In this systematic review and meta-analysis of 21 prognostic studies, researchers examined if a prediction of cancer therapy–related cardiac dysfunction (CTRCD) could be made assessing left ventricular global longitudinal strain (GLS). The studies included data of 1,782 patients with cancer, including breast cancer, hematologic malignancies, or sarcomas, treated with anthracyclines with or without trastuzumab. Outcomes revealed a higher risk of CTRCD in correlation to worse absolute GLS during chemotherapy and a greater relative deterioration compared with baseline. Following the initiation of possibly cardiotoxic chemotherapy with anthracyclines with or without trastuzumab, GLS measurement had a good prognostic ability for ensuing CTRCD.